Millions of individuals diagnosed with breast cancer could potentially bypass chemotherapy, a significant advancement stemming from a new DNA test that accurately distinguishes between patients likely to benefit from the rigorous treatment and those who are not. The international trial, involving over 4,000 newly diagnosed patients aged 40 and above across six countries, found that more than two-thirds of participants could safely forgo chemotherapy and be treated with hormone therapy alone, according to its recently published results.
Understanding the Impact of Chemotherapy
Chemotherapy, while a powerful tool in fighting cancer, carries a substantial burden of side effects. These can include debilitating fatigue, severe nausea, hair loss, a compromised immune system, and potential long-term fertility issues. For many patients, the prospect of enduring these side effects can be as daunting as the cancer diagnosis itself.
The Prosigna Gene Test: A New Era of Precision
The groundbreaking study, led by University College London (UCL), utilized the Prosigna gene test. This sophisticated test analyzes the activity of 50 genes intricately involved in breast cancer growth. By measuring gene activity, the test calculates a patient’s individual risk of the disease recurring after initial treatment.
In the trial, patients who received a low score on the Prosigna test—representing over two-thirds of the participants—were excluded from chemotherapy. The results showed a remarkable five-year survival rate of 93.7% for this group. For comparison, patients who received chemotherapy as part of their treatment had a slightly higher five-year survival rate of 94.9%.
Contexting Breast Cancer Treatment
The standard primary treatment for breast cancer typically involves surgery to remove the tumor. Following surgery, chemotherapy is often recommended to reduce the risk of the cancer returning. It is also a common recommendation for patients with early-stage breast cancer that has already spread to nearby lymph nodes.
However, oncologists have expressed concerns that for certain common types of breast cancer, the benefits of chemotherapy may be marginal for a significant number of patients. This trial sought to address that uncertainty by providing a more precise method for treatment selection.
Potential for Widespread Impact
UCL estimates that this new approach could enable more than 5,000 National Health Service (NHS) patients annually in the UK alone to avoid chemotherapy. This represents a substantial shift towards more personalized and less burdensome cancer care.
Karen Bonham, a 64-year-old trial participant from Cardiff, shared her relief, describing the study’s findings as “immense relief” and feeling “like Christmas.” Bonham successfully avoided chemotherapy due to the Prosigna test, instead receiving eight years of radiotherapy and hormone therapy. “Cancer diagnosis and treatment can be shocking,” she stated. “It certainly propels you into a world of uncertainty. Life priorities realign – you simply want to survive.”
Expert Endorsement and Future Directions
The study’s findings are set to be presented at the American Society of Clinical Oncology’s annual meeting in Chicago, the world’s largest cancer conference. Professor Rob Stein, the trial’s chief investigator and a professor of breast oncology at the UCL Cancer Institute, hailed the results as a “significant step toward more personalised treatment.”
“The trial has successfully used tumour biology to guide decisions rather than relying solely on traditional clinical features,” Professor Stein explained. “For patients, this means many may be spared the physical and emotional burden of chemotherapy and its potential long-term side effects. For health systems, it represents a more efficient and evidence-based use of resources.”
Looking Ahead
While the trial focused on patients over 40, UCL indicated that it is not yet known whether these findings apply to younger individuals. Further results regarding this demographic are expected in the coming years. The successful integration of this gene test into routine clinical practice could fundamentally alter treatment pathways for millions, offering a less toxic and more targeted approach to managing breast cancer.
Leave a Reply